Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care
04 Agosto 2021 - 9:30AM
Daxor
Corporation (NYSE
MKT: DXR), the global leader in blood volume measurement
technology, today announces new data published in the journal
Critical Care showing Daxor’s unique BVA-100 diagnostic blood test
provides insights into the pathophysiology of volume derangements
and capillary distress in critically ill COVID-19 patients enabling
improved care.
The Research Letter titled “Blood volume and
albumin transudation in critically-ill COVID-19 patients” studied
the abnormal blood volume profiles in mechanically ventilated
patients admitted to the ICU at a leading medical center in New
York. The data shows that COVID-19 patients suffer from significant
capillary damage and blood volume deficits that care teams became
aware of through the use of the Daxor BVA-100 blood test.
Dr. Jan Bakker, the author of the research
letter, stated “Fluid resuscitation in COVID-19 patients could
benefit from knowing the blood volume and capillary leak rate of
patients as they are subject to significant leak and related
hypovolemia.” Dr. Bakker noted that he has initiated a multi-center
prospective study utilizing the BVA-100 blood test to understand
fluid imbalances in COVID-19 patients as a result of this initial
research. The study has passed the half-way mark of enrollment at
Wake Forest School of Medicine, Oregon Health & Science
University and NYU Langone Health (NCT04517695).
“Having this preliminary data published in such
a prestigious medical journal as Critical Care highlights the
importance of Daxor’s BVA technology in helping clinicians
understand COVID-based volume derangements to improve care and
outcomes,” said Michael Feldschuh, CEO and President of Daxor.
“Daxor’s BVA test is the first and only diagnostic test cleared by
FDA that offers insights into patients’ blood volume with a 98%
accurate measure of plasma and red cell volume. Prior research in
the area of critical care has shown that BVA can dramatically
improve fluid management and reduce mortality in the ICU. We look
forward to the results of the ongoing trial given this promising
research letter from Dr. Bakker.” About
Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global
leader in blood volume measurement technology focused on blood
volume testing innovation (organized as an investment company with
fully-owned innovative medical instrumentation and biotechnology
operations). We developed and market the BVA-100® (Blood Volume
Analyzer), the first diagnostic blood test cleared by the FDA to
provide safe, accurate, objective quantification of blood volume
status and composition compared to patient-specific norms. The BVA
technology enhances hospital performance metrics in a broad range
of surgical and medical conditions, including heart failure and
critical care, by informing treatment strategies, resulting in
significantly improved multiple measures of patient outcomes.
Daxor's mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024